169 results about "Oxyde nitrique" patented technology

The invention discloses an ultrasonic activation type piezoelectric gel dressing and a preparation method and application thereof.The surface of a system is an antibacterial hydrogel layer, the antibacterial hydrogel layer is composed of polyethyleneimine (PEI) and polyvinyl alcohol (PVA) cross-linked hydrogel, and ultrasound and current can be transmitted to a deep area; bT-dNO piezoelectric nanoparticles are packaged inside, and BT-dNO is prepared by coating a nitric oxide (NO) donor on the surface of piezoelectric barium titanate (BT) subjected to hydroxylation and dopamine modification. Under the stimulation of low intensity focused ultrasound (LIFU), the donor can release NO as required, and the BT nanoparticles can generate reactive oxygen species (ROS) and output piezoelectric current. The dressing system has an effective combined repair effect, excellent biocompatibility and good anti-inflammatory ability.

The invention discloses an application of squalene or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing or treating endotoxemia. Experiments show that squalene significantly relieves LPS-induced endotoxemia liver injury through a multi-target mechanism, squalene not only relieves inflammatory response by inhibiting release of inflammatory factors, but also relieves oxidative stress by activating an antioxidant pathway, and the squalene has dual action mechanisms. The invention further provides application of the squalene-containing composition to preparation of the medicine for treating endotoxemia, squalene and glucocorticoid show a synergistic effect in the aspect of inhibiting TNF-alpha, AST can be reduced more remarkably by combining squalene and glucocorticoid, and the effect of dual inhibition of inflammatory mediators is achieved. Besides, the composition of the inducible nitric oxide synthase and squalene is applied to the preparation of the medicine for treating endotoxemia, and the inducible nitric oxide synthase inhibitor can inhibit the activity of iNOS, so that the excessive generation of nitric oxide is reduced, and the inflammatory reaction is further inhibited synergistically.

The invention discloses a silicone rubber plate for blending bone cement and a preparation process thereof, and relates to the technical field of silicone rubber plates, the preparation process comprises the following steps: adding silicone rubber, fluorinated silicone rubber and a double vulcanizing agent into a kneading machine, adjusting roller spacing, preparing into tablets, and vulcanizing to obtain a silicone rubber raw sheet; cutting and forming a silicone rubber raw sheet, and ultrasonically cleaning in ethanol for later use; the preparation method comprises the following steps: treating the surface of a cleaned raw silicon rubber sheet by using a nanosecond laser and performing laser drilling treatment by using a picosecond laser in sequence, then preparing nano silicon dioxide through hydrolytic condensation of ethyl silicate to fill holes, cleaning a drilling area on the surface by using the picosecond laser, and finally performing hydrophobic modification by using hexamethyldisilazane to obtain the super-hydrophobic silicon rubber plate. The preparation method comprises the following steps: carrying out sulfydryl modification on the surface of a super-hydrophobic silicone rubber plate, grafting ammonium bromide on the surface of the super-hydrophobic silicone rubber plate through an ultraviolet sulfydryl olefin reaction, grafting through an L-proline reaction, and finally absorbing nitric oxide to be saturated to obtain the silicone rubber plate for blending the bone cement.

Provided herein are compounds of Formula (I), Formula (II), and Formula (III) or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7 and A are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), Formula (II), or Formula (III) and methods of using a compound of Formula (I), Formula (II), or Formula (II), e.g., in the treatment of a mental health disease or disorder.

Disclosed is a process for the synthesis of mono- and bis-nitrosylated propanediols, as well as compositions and pharmaceutical formulations that includes the compounds. The process proceeds by reacting a corresponding propanediol that is not nitrosylated with a source of nitrite, optionally in the presence of a suitable acid. When the source of nitrite is an organic nitrite, reacting step is performed in a suitable organic solvent, and when the source of nitrite is an inorganic nitrite, the reacting step is performed in a bi-phasic solvent mixture comprising an aqueous phase and a non-aqueous phase. Also disclosed are methods of treating a condition wherein administration of nitric oxide (NO) has a beneficial effect by administering said compounds, compositions or formulations.

The nitric oxide gel for treating endometrial injury is composed of a gel matrix and a nitric oxide gas solution, the nitric oxide gas solution is uniformly dispersed in the gel matrix, and the volume ratio of the gel matrix to the nitric oxide gas solution is 3: 1-1: 3. The gel matrix is composed of one or more of poloxamer and derivatives thereof, povidone, carbomer and cellulose derivatives, and the nitric oxide gas solution is formed by dispersing nitric oxide gas in absolute ethyl alcohol or water-free and oxygen-free polyhydric alcohol which is in a liquid state at the temperature of 25 DEG C. According to the nitric oxide gel for treating the endometrial injury, the limitation bottleneck of the nitric oxide gel for treating the endometrial injury is overcome, meanwhile, the safe, effective, convenient and economical requirements of clinical treatment are met, and the effect of nitric oxide on treating the endometrial injury is fully exerted.

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations comprising them and their use, alone or in combination with one or more additional agents, for the treatment of various diseases wherein the concentration of nitric oxide (NO) and / or the concentration of cyclic guanosine monophosphate (cGMP), or both, is increased, such as, for example, the concentration of nitric oxide (NO) and / or the concentration of cyclic guanosine monophosphate (cGMP). Or regulation of the NO pathway is desirable. In some embodiments, the compound is a compound of Formula I or a pharmaceutically acceptable salt thereof. # imgabs0 #

The present invention belongs to the field of agarwood, and in particular to a kind of 2-(2-phenylethyl) chromone and lignan heterocompound and its application. The present invention uses the agarwood produced by thick-leaved agarwood tree as raw material, and after reflux extraction, successively adopts silica gel, Sephadex LH-20 gel, high performance liquid chromatography and other chromatographic techniques to separate and purify to obtain 1 monomer compound, and its structure is identified by spectral methods such as mass spectrometry and nuclear magnetic resonance and combined with physicochemical properties. It is retrieved as a new compound by SciFinder and named as thick-leaved agarwood alcohol (aquicrassnol), which is the first heterocompound formed by 2-(2-phenylethyl) chromone and lignan found in agarwood. It has been verified by experiment that the compound has an inhibitory effect on the production of nitric oxide in mouse mononuclear macrophage RAW264.7 induced by lipopolysaccharide, and its half-maximal inhibitory concentration value is 47.53±2.14μmol / L, which has anti-inflammatory activity.

The invention discloses amphiphilic polyurethane capable of realizing post-crosslinking and controllable release of nitric oxide as well as a preparation method and application of the amphiphilic polyurethane, and belongs to the technical field of materials for glucose detection. A main chain of the polyurethane is composed of a hydrophobic chain segment, a hydrophilic chain segment, a polydimethylsiloxane chain segment and a-O-(CH2) n-Se-Se-(CH2) n-O-group, wherein n is equal to 1 to 5; a side chain containing an epoxy group is also arranged on the main chain. According to the polyurethane material, on the basis that a main chain contains a double-selenium chain segment, a side chain containing an epoxy group is introduced into the main chain, so that the polyurethane material has a post-crosslinking function, a polyurethane glucose limiting film can be prepared by adding a crosslinking agent in the later period, the mechanical strength and hardness of the polyurethane glucose limiting film can be improved, and the degradation rate of a double-selenium structure is reduced; and the shelf life of the CGM product is prolonged.

A composition and method of providing nitric oxide and nitrite therapy to patients whereby a therapeutic amount is bioavailable within approximately 30 minutes of administration. In embodiments of the invention, nitric oxide is produced in the oral cavity.

This utility model relates to an innovation of a carotid artery vasodilator that can be used at home and in the emergency room as a supplement to drug treatment for conditions such as carotid artery obstruction in the neck region. It increases the production of nitric oxide mediated by endothelial nitric oxide synthase in the intact endothelial layer of the carotid artery, which is located on the inner surface of the neck brace. It can be applied for a certain period of time for each patient. The intermittent or continuous operation function can be selected through an adjustable power circuit. It only affects the lesion area and does not affect the patient's peripheral blood vessels. It can be used in situations where nitrates may be prohibited. It prevents the reduction of blood flow to the brain tissue that may occur due to jugular venous constriction. The flexible structure of the applicator neck brace (9) can be maintained in the application area for a long time and includes a pulsed magnetic field (PMF).

The invention discloses an MT (melatonin) and SNP (single nucleotide polymorphism) compound preservative as well as preparation and application thereof, and relates to the field of compound preservative films. A nitric oxide donor sodium nitroprusside (SNP); tween-80 (Tween-80) is added into auxiliary components to serve as an emulsifying agent, MT and SNP are dissolved in a proper amount of water and evenly stirred, then Tween-80 is added, and the MT and SNP compound preservative is prepared, according to the MT and SNP compound preservative and preparation and application thereof, MT and SNP are natural or quasi-natural components, compared with chemical preservatives, the MT and SNP have smaller potential harm to the environment and the human body, MT and SNP are used in a compound mode, and therefore the MT and SNP compound preservative has the beneficial effects that the MT and the SNP are more environmentally friendly and more environmentally friendly. MT and SNP cooperate with each other to improve the fresh-keeping effect, the antioxidant effect of MT can reduce oxidative damage in the fruits, SNP promotes endogenous NO generation, can regulate signal transduction in the fruits and further inhibits respiration and ethylene synthesis of the fruits, maturing and aging of the fruits are delayed from different angles through cooperation of MT and SNP, and the fresh-keeping effect of the fruits is improved. Meanwhile, the MT and the NO can cooperatively regulate and control signal transduction in the plant body, and the action time of the NO in the fruit body is prolonged.

The present invention relates to the technical field of pharmaceuticals, and in particular to a class of nitric oxide (NO) donor-containing compounds or pharmaceutically acceptable salts, a preparation method therefor, a pharmaceutical composition, and a use thereof in the treatment or prevention of an ocular hypertension-related ophthalmic disease and an optic nerve injury-related disease.

The invention relates to the technical field of air detection, and in particular to a multi-point in-situ detection device for nitrous acid and nitric oxide, comprising a shunt collection pipeline, a multi-section extractor, an air suction pump, a cleaning circulation pipeline and a circulation cleaning device; the shunt collection pipeline is installed in a collection area, and the shunt collection pipeline is provided with a plurality of collection ends distributed in different collection areas; the multi-section extractor is installed at the output end of the shunt collection pipeline, the interior of the multi-section extractor is connected with a nitrous acid detector and a nitric oxide detector, the air suction pump is connected with the shunt collection pipeline, and the air suction pump is used to suck the gas inside the shunt collection pipeline; the cleaning circulation pipeline is installed above the shunt collection pipeline, and the cleaning circulation pipeline is provided with a plurality of liquid outlet ends, and the liquid outlet end of the cleaning circulation pipeline is connected with the shunt collection pipeline; the input end of the circulation cleaning device is connected with the shunt collection pipeline, and the output end of the circulation cleaning device is connected with the cleaning circulation pipeline. The invention can effectively improve the detection efficiency and reduce the detection cost at the same time.

The present invention relates to a liquid nitric oxide releasing solution (NORS) comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of nitric oxide gas (gNO). The present invention also relates to a liquid NORS comprised of at least one nitrite compound having a concentration of no greater than about 0.5% w / v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment of a wound in a human, the method comprising administering to the human a liquid NORS comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment, prevention, or reduction of incidence of a disease or disorder in a human in need thereof, the method comprising administering to the human a liquid NORS comprised of at least one nitrite compound at a concentration of no greater than about 0.5% w / v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO.

The invention provides a tissue engineering heart valve stent with a sulfonated nano-enzyme coating as well as a preparation method and application of the tissue engineering heart valve stent, and belongs to the technical field of medical materials. The invention relates to a tissue engineering heart valve stent with a sulfonated nano-enzyme coating, which comprises an acellular matrix carrier, ruthenium / iridium-tannic acid nano-enzyme loaded on the acellular matrix carrier, and a sulfonated polymer coating fixed on the acellular matrix carrier and / or the surface of nano-particles through ultraviolet polymerization, the ruthenium / iridium-tannic acid nano-enzyme is formed by tannic acid TA, Ru < 3 + > and Ir < 3 + > through coordination. According to the invention, through double bionic activities of superoxide dismutase and nitric oxide synthase of ruthenium / iridium-tannic acid nano-enzyme and through the super-hydrophilicity and electrically neutral surface of the sulfonated polymer coating, collaborative regulation and control of O2-NO cascade catalysis and interface functions in a pathological microenvironment are realized; the structural and functional in-situ regeneration of the tissue engineering heart valve stent is promoted.

Compositions and methods are presented in which a nitric oxide precursor, formed (preferably) from the reaction of a thiol-containing compound and a nitrosating compound, decomposes to form nitric oxide within a sealed delivery system that allows for mobile sanitation; from which the sample compartment can be separated from the nitric oxide releasing compartment with a secondary seal, then subsequently detached without altering the sterilized portion of the package.

The present application relates to a nitric oxide donor-type compound and use thereof in the preparation of a medicament for preventing and / or treating ophthalmic diseases such as glaucoma and ocular hypertension. The compound has a structure represented by formula (I), or is a stereoisomer, tautomer, solvate, metabolite, pharmaceutically acceptable salt, or prodrug of the structure represented by formula (I).

The invention discloses a cardiovascular stent coating capable of rapidly reconstructing endothelium and releasing nitric oxide for a long time, a preparation method and a stent. The cardiovascular stent coating comprises a dopamine / hexamethylenediamine-copper coating and multiple functional substances combined with the dopamine / hexamethylenediamine-copper coating, and the multiple functional substances comprise an NO precursor, endothelial polysaccharide with the anticoagulation characteristic and growth factors capable of specifically adhering EC. The cardiovascular stent coating provided by the invention is grafted with various functional substances such as endothelial polysaccharide, growth factors capable of specifically adhering EC, NO precursors and the like, so that the defects of low NO yield, poor anticoagulation effect, incapability of quickly promoting re-endothelialization in an early stage and the like of a traditional coating are favorably improved. According to the invention, the cardiovascular stent is endowed with various functions of adhering EC, increasing anticoagulation, providing enough NO under the condition of existence or absence of an endogenous NO donor and the like, so that rapid reendothelialization is promoted, thrombosis and restenosis are prevented, and the long-term curative effect and safety of the cardiovascular stent are finally improved.

A method includes mixing a liquid carrier and a powder formulation including an S-nitrosothiol (RSNO) powder to form a nitric oxide generating solution; and within a predetermined time of mixing, introducing the nitric oxide generating solution into an inflatable and nitric oxide permeable balloon of a urinary catheter that is inserted in a patient.

The present application relates to an activated stem cell microcapsule, a preparation method and application thereof. The activated stem cell microcapsule is prepared by the following method: taking mesenchymal stem cells, culturing the mesenchymal stem cells in a culture medium containing resveratrol, collecting the supernatant, and centrifuging the supernatant by differential centrifugation to obtain the activated stem cell microcapsule; the concentration of the resveratrol in the culture medium is less than 1.5 micromoles per liter. Then the activated stem cell microcapsule is mixed with a nitric oxide donor for incubation to obtain an activated stem cell microcapsule loaded with a nitric oxide donor. The activated stem cell microcapsule and the activated stem cell microcapsule loaded with the nitric oxide donor provided by the present application have good blood vessel repair effect and can be used for preparing a drug for treating peripheral vascular lesions.

The invention relates to a nitric oxide donor based on heparin sodium and a preparation method and application thereof, the method comprises the following steps: (1) dissolving heparin sodium in a 2-(N-morpholino) ethanesulfonic acid buffer solution, adding an activator, and carrying out a reaction to obtain a reaction solution A; (2) adding beta-mercaptoethylamine into the reaction solution A, and continuously reacting to obtain a reaction solution B; (3) dialyzing the reaction solution B to obtain a solution C; and (4) adding tert-butyl nitrite into the solution C, and reacting to obtain the heparin sodium-based nitric oxide donor. Wherein in the step (1), the activating agent is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide or hydrochloride of the 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide. According to the prepared heparin sodium-based nitric oxide donor, the nitric oxide release time is prolonged, and the problem that the half-life period of nitric oxide is short is solved.

The invention provides a near-infrared light NIR response-based dual-regulation nano drug delivery system and application thereof, the nano drug delivery system takes mesoporous silica as a carrier, and alendronate sodium is coupled on the surface of the carrier to increase bone targeting; mesopores in the carrier are blocked by rhodamine RH, nitric oxide NO can be consumed to generate rhodamine B, and bioactive drugs in the carrier are released. The invention constructs a systemic drug carrier with bone targeting and diabetic bone microenvironment response release, and solves the problems that the bone healing ability of diabetic patients is significantly reduced, and traditional local treatment is difficult to effectively improve systemic bone microenvironment disorder; the problems that an existing local drug system cannot be released according to needs, local NO and NO in bone marrow are difficult to efficiently remove, and macrophages are difficult to transform to repair-promoting M2 type are solved.

The application belongs to the technical field of electrochemical sensing, and particularly relates to an electrochemical sensing electrode with detection and anti-biofouling functions, a preparation method and application thereof. The electrochemical sensing electrode comprises a conductive substrate and a MOF-919 material loaded on the conductive substrate, and function mode switching is realized through external potential regulation. In the detection mode, a first working voltage is applied for nitrite oxidation detection; and a second working voltage is applied to release nitric oxide in situ by reducing nitrite to inhibit microbial adhesion on the electrode surface. The application does not need to additionally set an independent antibacterial layer or add an antibacterial agent, realizes the interface anti-microbial adhesion function while maintaining good electrochemical response performance of the electrode, and significantly improves the stability of long-term use in complex samples. The application provides a new technical path for anti-pollution design of an electrochemical sensing interface.

The nitric oxide high-dispersity W / O emulsifiable paste is composed of an emulsifiable paste substrate, an emulsifier and a nitric oxide gas solution, the nitric oxide gas solution is uniformly dispersed in the emulsifiable paste substrate, and the volume ratio of the emulsifiable paste substrate to the emulsifier to the nitric oxide gas solution is 4: 1: 1-1: 1: 4. The emulsifiable paste substrate is composed of one or more of plant-derived vegetable oil or hydrogenated vegetable oil, saturated hydrocarbon, ester chemically synthesized or semi-synthesized by higher fatty acid and higher fatty alcohol and a mixture thereof; the emulsifier is composed of one or more of soap, higher fatty alcohol, polyol ester, fatty alcohol sulfate or sodium and polyoxyethylene ether derivatives, and the nitric oxide gas solution is formed by dispersing nitric oxide gas in a water-free and oxygen-free polyol solution which is in a liquid state at the temperature of 25 DEG C. The nitric oxide high-dispersity W / O cream overcomes the problems that nitric oxide molecules are poor in stability and prone to oxidation failure and the like, and is used for achieving the treatment effect of nitric oxide on body diseases, especially the treatment effect of nitric oxide on skin and mucosa inflammation.

The invention relates to a nitric oxide donor type compound and application thereof in preparation of drugs for preventing and / or treating ophthalmic diseases such as glaucoma and intraocular hypertension. The compound has a structure as shown in a formula (I), or a stereoisomer, a tautomer, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the structure as shown in the formula (I).

The present invention belongs to the field of pharmaceutical chemistry, and particularly relates to a hyaluronic acid derivative or salt having dual responsiveness to nitric oxide and reactive oxygen species, a preparation method thereof, and an application thereof; the present invention prepares HA-o-phenylenediamine-maleic acid-Vc by chemically grafting hyaluronic acid; it has environmental responsiveness, good biocompatibility, excellent injection properties, and good biological environment responsiveness, can perform intelligent response and scavenging according to the concentrations of reactive oxygen species and nitric oxide in the environment, reduce the concentration level of excessive environmental adverse factors, and has excellent stability, and can be used in the fields of drug intelligent delivery and cosmetics.

The present application relates to a kind of heparin sodium-based nitric oxide donor and its preparation method and application, the method includes the following steps: (1) heparin sodium is dissolved in 2-(N-morpholino) ethanesulfonic acid buffer solution, adding activating agent, reaction is carried out, and reaction liquid A is obtained;(2) to reaction liquid A, continue to react to obtain reaction liquid B by adding β-mercaptoethylamine;(3) reaction liquid B is dialyzed, and solution C is obtained;(4) to solution C, nitrous acid tert-butyl ester is added, and the heparin sodium-based nitric oxide donor is obtained by reaction;Wherein, in step (1), the activating agent is 1-ethyl-3-(3-dimethylaminopropyl) carbonyl diimide or its hydrochloride salt.The heparin sodium-based nitric oxide donor prepared in the present application prolongs the release time of nitric oxide, and solves the problem of short half-life of nitric oxide.

This invention discloses a carrier-free, self-driven nanorobot empowered by nitric oxide, its preparation method, and its applications, belonging to the field of biomedical technology. This invention involves forming a hybrid nanoassembly by driving a nitric oxide donor drug and a photothermal photosensitizer molecule through non-covalent interactions. The surface of the hybrid co-assembled nanoassembly is modified with one or both of polyethylene glycol (PEG) modifiers and PEG thrombofibrin-targeting peptides. The molar ratio of the nitric oxide donor drug to the photothermal photosensitizer molecule is 1:10 to 10:1. The preparation method of this invention is stable, convenient, simple, and practical. The resulting thrombotargeting, nitric oxide donor drug, and photothermal photosensitizer hybrid nanoassembly exhibits extremely high drug loading capacity, enabling efficient co-loading of the hybrid nanoassembly and efficient photothermal-nitric oxide thrombolysis. This provides a novel and efficient drug delivery strategy for the treatment of cerebrovascular diseases such as thrombosis and ischemic stroke.

Provided herein are compounds of Formula (I), Formula (II), and Formula (III) or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7 and A are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), Formula (II), or Formula (III) and methods of using a compound of Formula (I), Formula (II), or Formula (III), e.g., in the treatment of a mental health disease or disorder.